Injective Public-Source Startup Diligence Report
Proceed only to confirmatory diligence if underwriting a differentiated finance-focused L1 with exchange/orderbook, EVM/CosmWasm, USDC/CCTP, regulated-futures adjacency and active developer tooling. Gating questions are whether current adoption/economics support historical unicorn valuation and whether regulatory/security/entity risks are controlled.
Injective Public-Source Startup Diligence Report
Injective is public-source supportable as an active, private, unicorn-class crypto finance infrastructure company/protocol ecosystem: CB Insights lists a $1B unicorn row, The Block reported a $1B+ token-sale valuation, LinkedIn lists Injective Labs as privately held, active official 2026 sources exist, and public repositories show current technical activity. Public evidence is insufficient for investment underwriting without private financial, capitalization, token, contract, legal and security materials.
Historical unicorn/funding signals are public, but current revenue, margins, burn, runway, cap table, token treasury and valuation bridge are not.
Diligence request: Request financials, forecast, cap table, token ledger, financing docs and valuation bridge.
dYdX, Hyperliquid, Sei, Solana and Ethereum/L2 ecosystems compete for finance apps, traders, liquidity and developers.
Diligence request: Request market share, liquidity depth, active developer/user cohorts, incentive spend and win/loss analysis.
INJ token sale history, DeFi exchange/orderbook functionality, INJ futures, terms restrictions and global access require multi-jurisdiction counsel review.
Diligence request: Request token/exchange/derivatives/sanctions counsel memos and compliance-control evidence.
DeFiLlama/CoinGecko proxies are point-in-time and volatile, and appear modest relative to historical $1B valuation.
Diligence request: Request historical metrics, liquidity depth, fee capture, active users and sensitivity to token/market cycles.
Exchange/orderbook, oracle, IBC/bridges, EVM/WASM, SDKs and open-source components create critical failure modes.
Diligence request: Request audits, incident history, dependency inventory, bug bounty records and maintainer map.
Economics among Injective Labs, Foundation, protocol fees, token treasury, validators and ecosystem apps are not publicly mapped.
Diligence request: Request entity chart, intercompany agreements, app ownership, revenue-recognition memo and protocol fee split.
Public roster/headcount signals are partial; org chart, board, compensation, incentives and turnover are private.
Diligence request: Request org chart, board roster, management bios, HRIS headcount, compensation, incentives and turnover.
Public legal searches were limited; material contracts, IP schedule, insurance, regulatory correspondence and legal opinions are not public.
Diligence request: Request litigation schedule, counsel memos, IP/OSS inventory, material contracts and insurance policies.
Public evidence verifies unicorn and funding signals, but company financials, forecasts, cap table, token ledger, debt and tax/accounting records are not public.
not publicly verifiable confidence: high
No audited or management financial statements, revenue breakdown, backlog or A/R aging were public; protocol metrics are only proxies.
| item | public evidence | implication | follow up |
|---|---|---|---|
| Financial statements | Not public. | Cannot underwrite revenue, burn or cash flow. | Audited/unaudited statements and management reports. |
| TVL/stablecoins | DeFiLlama: TVL $13.44M; stablecoins $15.14M. | Adoption proxy, not revenue. | Historical TVL and fee capture. |
| Fees/volumes | 24h fees $13.1K; DEX $0.92M; perps $13.68M. | Activity appears modest relative to unicorn valuation. | Revenue recognition and fee split. |
| INJ market data | CoinGecko: price about $4.91; 115 exchanges; 190 markets. | Token liquidity/volatility risk. | Treasury, lockups and market-maker agreements. |
not publicly verifiable confidence: high
No board-approved forecast or sensitivity model was public; growth drivers are inferred from product/partner announcements.
not publicly verifiable confidence: medium
LinkedIn/SEC screen supports private status and CoinGecko supports token-market visibility, but shares, holders, options, warrants, debt, token treasury and off-balance-sheet items are not public.
| item | public evidence | implication | follow up |
|---|---|---|---|
| Private status | LinkedIn privately held; SEC ticker screen found no obvious public issuer. | Supports private-status screen. | Corporate records and M&A search. |
| Equity holders/options | Not public. | Dilution/preferences unknown. | Fully diluted cap table and option ledger. |
| INJ token | CoinGecko market visibility but no treasury/unlock ledger. | Potential token overhang and governance exposure. | Token allocation, wallets and lockups. |
| Financing instruments | 2021 token placement and 2022 financing reported; terms not public. | Rights and preferences unknown. | Purchase agreements, side letters and legal memos. |
partially verified confidence: high
Public financing history includes CB Insights $1B row, 2021 $10M token placement at $1B+ valuation, 2022 $40M raise and $59.8M aggregate estimate. Tax and accounting policies are not public.
| item | public evidence | implication | follow up |
|---|---|---|---|
| CB Insights row | $1B valuation; joined 2021-04-20; US/New York; Financial Services; Pantera/Cadenza/BlockTower | Unicorn-class public database signal. | Current cap table and valuation bridge. |
| 2021 token placement | The Block: $10M private placement at $1B+ valuation from Mark Cuban, Pantera, BlockTower, Hashed, CMS, QCP. | Confirms token financing and legal diligence trigger. | Token-sale documents and legal memo. |
| 2022 financing | Injective announced $40M from Jump Crypto and BH Digital. | Major publicized financing. | Financing terms and proceeds. |
| Aggregate funding | Crypto Fundraising: about $59.8M total raised. | Round completeness proxy. | Reconcile equity/token proceeds. |
Funding may mix equity and token economics.
Injective has a finance-L1 product surface with exchange/orderbook, oracle, interoperability, EVM/CosmWasm, Helix/Mito and USDC/CCTP signals; economics, benchmarks and security proof are private.
partially verified confidence: medium
Public products/components include Injective L1, exchange/orderbook/FBA, oracle, EVM/CosmWasm, Helix, Mito, native USDC/CCTP and INJ futures adjacency.
| item | public evidence | implication | follow up |
|---|---|---|---|
| Injective L1 | Fast L1 for DeFi and finance apps. | Core product category. | Product P&L and benchmarks. |
| Exchange/orderbook/oracle | Orderbook/FBA and oracle module with relayers/Band IBC. | Differentiated but critical dependency. | Oracle controls and audits. |
| Helix/Mito | Spot/derivatives exchange; automated trading vaults/launchpad. | Ecosystem app breadth. | Ownership/economics and user cohorts. |
| Native EVM + USDC/CCTP | EVM mainnet and native USDC/CCTP announced. | Developer/liquidity growth driver. | Adoption, audits and contracts. |
| item | public evidence | implication | follow up |
|---|---|---|---|
| Throughput | Docs: sustained 25,000 tx/s; theoretical 600,000 tx/s. | Supports performance positioning. | Independent benchmark. |
| Latency | Docs: 650ms block time. | Important for trading UX. | Uptime and latency monitoring. |
| Fees | Docs: about $0.0003 standard fee. | Price competition claim. | Fee schedule and revenue split. |
| Interoperability | IBC/Ethereum, EVM, USDC/CCTP across 20+ chains. | Growth and security dependency. | Bridge/CCTP audits and volumes. |
Company-authored claims require testing.
Public evidence shows ecosystem applications and partner announcements, but no top-customer, revenue-by-customer, churn or supplier-spend data. Public metrics are adoption proxies.
not publicly verifiable confidence: medium
No top-15 customer list was public; Helix/Mito and DeFiLlama are application/activity proxies, not customer revenue.
| item | public evidence | implication | follow up |
|---|---|---|---|
| Helix | Premier decentralized spot and derivatives exchange. | Visible trading app. | Revenue split and MAU. |
| Mito | Automated trading vaults and launchpad. | Vault/launchpad app surface. | Vault performance and revenue. |
| Bitnomial futures | INJ futures live on CFTC-regulated Bitnomial. | Regulated derivative access. | Listing terms and volume. |
| USDC/CCTP and Musicow | Native USDC/CCTP and music IP partnership announced. | Liquidity/RWA relationship signals. | Contracts and launch KPIs. |
| item | public evidence | implication | follow up |
|---|---|---|---|
| Top 15 customers/apps | Not public; app/protocol proxies only. | Concentration unknown. | Customer/app list by revenue and volume. |
| 5%+ customers | Not public. | Major concentration risk hidden. | Revenue by customer/app/partner. |
| Severed relationships | Not public. | Lost liquidity/partners may be hidden. | Two-year churn/termination schedule. |
| Incentives versus revenue | Not public. | Subsidized activity may mimic demand. | Grants/incentives and fee capture. |
partially verified confidence: medium
Public strategic relationships include Bitnomial INJ futures, USDC/CCTP and Musicow; contract economics are not public.
not publicly verifiable confidence: high
Revenue by customer, top-app contribution and 5%+ concentration are not public, so customer-quality assessment must rely on weaker protocol and ecosystem proxies until management provides schedules.
not publicly verifiable confidence: medium
No public list of severed customer, partner or supplier relationships was found.
partially verified confidence: medium
Public dependencies include oracle/Band IBC, USDC/CCTP, open-source repositories, Bitnomial and other infrastructure; spend and contracts are private.
| item | public evidence | implication | follow up |
|---|---|---|---|
| Oracle relayers / Band IBC | Oracle module used by exchange module for external price data. | Critical trading dependency. | Relayer list, governance, SLA, incidents. |
| USDC/CCTP | Native USDC and cross-chain transfers announced. | Stablecoin/cross-chain dependency. | Circle terms and volumes. |
| Open-source SDK/core repos | Active public repos. | Developer tooling/security dependency. | Maintainers, audits, dependency inventory. |
| Bitnomial | INJ futures venue. | Regulated derivatives partner. | Agreement, surveillance and termination terms. |
Injective competes with specialized DeFi derivatives venues, high-frequency finance L1s and broad L1/L2 ecosystems; liquidity and distribution depth are critical.
partially verified confidence: medium
Competitors include dYdX, Hyperliquid, Sei, Solana and Ethereum/L2 ecosystems; competition is based on liquidity, latency, fees, developer tooling, compliance/institutional access, security and incentives.
| item | public evidence | implication | follow up |
|---|---|---|---|
| Injective | Finance-focused L1 with orderbook/EVM/interoperability claims. | Differentiated architecture. | Independent market-share and liquidity evidence. |
| dYdX | DeFi pro trading platform; 200+ markets. | Direct trading liquidity competitor. | Compare perps markets/depth. |
| Hyperliquid | Fully on-chain order book on L1. | Direct technical/liquidity competitor. | Compare volumes, latency, liquidity. |
| Sei / Solana | High-frequency EVM L1 and high-performance capital-markets network. | Competes for developers and finance apps. | Compare developer traction and app ecosystem. |
| item | public evidence | implication | follow up |
|---|---|---|---|
| Technology/fees | Docs claim high throughput, low latency and low fees. | Potential strength if benchmarked. | Independent benchmark and uptime. |
| Liquidity/adoption | DeFiLlama public TVL/volume/fees. | Real but volatile/modest proxy. | Market share and depth. |
| Distribution | CoinGecko exchange/market coverage and partnerships. | Broad token visibility. | Conversion to app usage/revenue. |
| Regulated access | Bitnomial INJ futures. | Institutional access signal. | Volume, open interest and legal analysis. |
GTM appears developer/ecosystem/community-led with token liquidity, partnerships and regulated-futures messaging; CAC, pipeline, quotas and budget are not public.
partially verified confidence: medium
Positioning centers on a finance-first L1 for builders, traders and institutions. Distribution uses docs/GitHub, ecosystem apps, token markets and partnership PR.
| item | public evidence | implication | follow up |
|---|---|---|---|
| Developer/docs/GitHub | Official docs and active SDK repos. | Developer acquisition. | Active developers and conversion. |
| Ecosystem apps | Helix and Mito product pages. | Trader/vault users. | MAU, fees and retention. |
| Token/exchange liquidity | INJ across 115 exchanges/190 markets. | Token-holder/trader distribution. | Liquidity quality and market-maker obligations. |
| Partnership/PR | Bitnomial, USDC/CCTP, Musicow. | Institutional/ecosystem credibility. | Revenue impact. |
| item | public evidence | implication | follow up |
|---|---|---|---|
| INJ futures | Live on Bitnomial per announcement. | Regulated derivatives narrative. | Listing agreement and volumes. |
| Native EVM | Mainnet launch with 30+ dApps/providers. | Developer ecosystem push. | App adoption and audits. |
| USDC/CCTP | Native USDC/CCTP live. | Stablecoin liquidity rail. | Circle terms and volumes. |
| Musicow | Music IP partnership. | RWA/content finance signal. | Rights and revenue share. |
not publicly verifiable confidence: medium
No major customer pipeline or relationship-status report is public; announcements are relationship signals only.
partially verified confidence: medium
Principal avenues appear to be developer adoption, app ecosystem growth, exchange/token liquidity, institutional derivatives access, stablecoin rails and RWA partnerships.
not publicly verifiable confidence: high
No sales compensation, quota, sales-cycle, pipeline-conversion or hiring model was public, preventing validation of productivity, CAC payback or budget efficiency from public sources.
| item | public evidence | implication | follow up |
|---|---|---|---|
| Sales compensation/quota | Not public. | Cannot assess productivity. | Comp plans, quotas and attainment. |
| Sales cycle/pipeline | Announcements only. | Forecast conversion unverified. | CRM pipeline and win/loss. |
| Grants/incentives | Not disclosed in reviewed sources. | Organic versus subsidized growth unclear. | Incentive budget and ROI. |
| Marketing budget/runway | Not public. | Execution capacity unknown. | GTM budget and runway. |
not publicly verifiable confidence: high
Budget sufficiency cannot be assessed because financials and GTM budget are not disclosed.
Public GitHub activity and product announcements demonstrate ongoing R&D; engineering org depth, roadmap cost, security posture, audits and dependency management remain open.
partially verified confidence: high
Injective Labs describes itself as R&D-focused/core contributor and public repositories show active SDK/core development; exact engineering headcount and security program are private.
| item | public evidence | implication | follow up |
|---|---|---|---|
| injective-ts | Apache-2.0; pushed 2026-05-19. | Active TypeScript tooling. | Maintainer map and dependencies. |
| sdk-go | Apache-2.0; pushed 2026-05-19. | Active Go tooling. | API stability and audit. |
| sdk-python | Apache-2.0; pushed 2026-05-19. | Active Python tooling. | Maintainer coverage. |
| injective-core | Pushed 2026-05-12; license NOASSERTION. | Core-chain activity plus license diligence need. | Core license, audits and critical maintainers. |
partially verified confidence: medium
Native EVM, USDC/CCTP, INJ futures and Musicow are visible roadmap/milestone signals; cost, critical path and release risk are not public.
| item | public evidence | implication | follow up |
|---|---|---|---|
| Native EVM mainnet | Launched with 30+ dApps/providers. | Developer expansion. | Active dApps, incidents and revenue. |
| USDC/CCTP | Live on mainnet. | Stablecoin/cross-chain rail. | Supply, transfer volume and contract terms. |
| INJ futures | Live on Bitnomial. | Regulated market access. | Volume/open interest and compliance. |
| Musicow RWA/music IP | Partnership announced. | RWA/content-finance pipeline. | Assets launched and revenue share. |
Public sources identify partial team/personnel data and benefits; full org chart, board, management bios, compensation, incentive plans, employee relations and turnover are private.
partially verified confidence: medium
No complete org chart is public; team page lists Eric Chen, Albert Chon and functional roles, but reporting lines are not public.
| item | public evidence | implication | follow up |
|---|---|---|---|
| Eric Chen | Team page listing; 2022 blog quote identified him as co-founder/CEO in extraction. | Public leadership signal. | Full bio, board role, references. |
| Albert Chon | Listed on team page. | Public team signal. | Full role, tenure and references. |
| Head of Business Development | Functional role visible on team page. | BD leadership presence. | Pipeline ownership and quotas. |
| Market Research / BD roles | Roles visible on team page. | Commercial/research capacity signal. | Full org chart. |
Partial roster only.
Reporting lines are illustrative and require company org chart.
partially verified confidence: medium
LinkedIn indicates 51-200 size band and 31 visible employees; The Block reported a 22-person team in 2021; careers page says teammates span the globe. Exact headcount is private.
| item | public evidence | implication | follow up |
|---|---|---|---|
| 2021 headcount | The Block: team of 22 and plan to double. | Historical scaling signal. | Actual hiring/attrition outcome. |
| Current size range | LinkedIn: 51-200, 31 visible employees. | Approximate private active company signal. | Exact HRIS by function/location/entity. |
| Global team | Careers page: teammates span the globe. | Distributed model. | Payroll and compliance by jurisdiction. |
| Benefits/retention | Tokens, PTO, office/remote, parental benefits referenced. | Qualitative employer proposition. | Compensation, grants, turnover. |
partially verified confidence: medium
Eric Chen and Albert Chon are public names; complete biographies, tenure, prior employment, board roles and references were not public.
not publicly verifiable confidence: medium
Compensation arrangements are not public; careers page qualitatively references benefits including tokens and PTO.
not publicly verifiable confidence: high
Incentive equity/token plans are not public, leaving fully diluted ownership, retention leverage, employee alignment and future dilution unavailable for outside verification.
not publicly verifiable confidence: medium
No public employee-relations problem log was found; absence is inconclusive because employment claims, contractor disputes and settlements can remain private or be held by affiliates.
not publicly verifiable confidence: medium
Turnover data is not public; careers page provides qualitative benefits/culture statements only.
Public legal review found active terms/restricted-person controls, selected no-hit CourtListener searches, regulated futures context and partial OSS license evidence; material legal data remains private.
inconclusive confidence: medium
CourtListener exact searches did not identify obvious Injective Protocol or INJ token cases; this is not legal clearance.
| item | public evidence | implication | follow up |
|---|---|---|---|
| Litigation | CourtListener exact searches returned zero selected hits. | No obvious cases, inconclusive. | Counsel-certified searches. |
| Public company screen | SEC ticker screen found no obvious Injective public-company ticker. | Supports private-status screen. | Corporate/M&A confirmation. |
| Regulated derivatives adjacency | INJ futures on Bitnomial; Bitnomial CFTC DCM/DCO/FCM disclosures. | Regulatory diligence trigger. | Listing agreement and legal memo. |
| Terms restrictions | Terms dated 2026-04-16 include prohibited-person notice. | Compliance signal, controls unverified. | Geofencing/sanctions control audit. |
not publicly verifiable confidence: medium
No public list of company-initiated lawsuits was found, so any affirmative IP, contract, employment or recovery actions would need confirmation through counsel and litigation schedules.
not publicly verifiable confidence: low
As a software/Web3 organization, conventional environmental exposure appears lower, but workplace safety, remote-work and data-security policies are not public.
partially verified confidence: medium
Public GitHub metadata shows permissive SDK licenses, but core license metadata, patents, trademarks, code inventory and IP assignments need review.
| item | public evidence | implication | follow up |
|---|---|---|---|
| Open-source licenses | SDKs Apache-2.0; core license NOASSERTION. | OSS/license diligence needed. | OSS inventory and contributor agreements. |
| Patents/trademarks/IP | Not verified publicly in-session. | Defensibility/infringement exposure unknown. | IP schedule and clearance searches. |
| Material contracts | Announcements only; contracts not public. | Hidden economics/indemnities possible. | Contract register and executed agreements. |
| Insurance | Not public. | Cyber/protocol/D&O exposure unknown. | Insurance schedule and claims history. |
not publicly verifiable confidence: high
Insurance coverage is not public, leaving D&O, E&O, cyber, crime, custody, smart-contract and key-person risk transfer unavailable for loss-severity assessment.
not publicly verifiable confidence: high
Material contracts with investors, partners, exchanges, market makers, validators, suppliers and app developers are not public.
inconclusive confidence: medium
No public regulatory action was found in this session, but terms restrictions and Bitnomial/CFTC-regulated futures context make token/derivatives/DeFi regulatory analysis critical.
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | CB Insights lists Injective as a unicorn with a $1B valuation, April 20, 2021 join date, United States/New York metadata, Financial Services industry and investors Pantera Capital, Cadenza Ventures and BlockTower Capital. | verified high | SRC-001 |
| EC-002 | Public-source status screen supports treating Injective Labs as private and active, with no obvious U.S. public-company ticker found and active official 2026 product/legal sources. | partially verified medium | SRC-019SRC-024SRC-002SRC-003SRC-015 |
| EC-003 | Injective announced a $40M financing from Jump Crypto and BH Digital and cited over 92M on-chain transactions and $7B cumulative dApp volume at that time. | partially verified medium | SRC-004 |
| EC-004 | The Block reported Injective raised $10M through a private placement token sale at a $1B+ valuation from investors including Mark Cuban, Pantera, BlockTower, Hashed, CMS and QCP, with a 22-person team and plan to double. | verified high | SRC-005 |
| EC-005 | Crypto Fundraising aggregates Injective total public fundraising at about $59.8M, including $40M in 2022 and $10M in 2021 rounds plus earlier launchpad/private/seed entries. | partially verified medium | SRC-006 |
| EC-006 | Injective positions itself as a fast Layer 1 blockchain for DeFi and finance apps, built for finance. | verified high | SRC-003 |
| EC-007 | Injective docs describe orderbook, MEV-resistant FBA, IBC/Ethereum interoperability, EVM smart contracts, AI tools, sustained 25,000 tx/s, theoretical 600,000 tx/s, 650ms block time and about $0.0003 standard fee. | partially verified medium | SRC-007 |
| EC-008 | Injective oracle docs say the oracle module supplies external price data to the exchange module, with governance-controlled relayers and Band IBC integration. | verified high | SRC-008 |
| EC-009 | Multiple Injective public repositories showed current public development activity near the access date, including TypeScript, Go and Python SDKs and core chain repository metadata. | verified high | SRC-009SRC-010SRC-011SRC-012 |
| EC-010 | DeFiLlama point-in-time metrics showed Injective TVL about $13.44M, stablecoins market cap about $15.14M, chain fees/revenue 24h about $13,101, DEX volume 24h about $921,819 and perps volume 24h about $13.68M. | verified medium | SRC-013 |
| EC-011 | CoinGecko showed INJ around $4.91 and calculated across approximately 115 exchanges and 190 markets at access time. | verified medium | SRC-014 |
| EC-012 | Injective announced US-regulated INJ futures live on Bitnomial, and Bitnomial states subsidiaries are CFTC-regulated as DCM/DCO/FCM. | partially verified medium | SRC-015SRC-016 |
| EC-013 | Injective announced native EVM mainnet launch with 30+ dApps/infrastructure providers and unified EVM/WASM assets, liquidity and modules. | partially verified medium | SRC-017 |
| EC-014 | Injective announced Circle-issued native USDC and CCTP live on Injective mainnet for cross-chain transfers across 20+ blockchains. | partially verified medium | SRC-018 |
| EC-015 | Injective announced a Musicow partnership to bring music IP on-chain. | partially verified medium | SRC-027 |
| EC-016 | LinkedIn lists Injective Labs as Software Development, Contributors to Injective, company size 51-200, privately held, with 31 visible employees. | partially verified medium | SRC-019 |
| EC-017 | Injective Labs team page lists Eric Chen and Albert Chon and shows business development and market research roles. | partially verified medium | SRC-020 |
| EC-018 | Injective Labs careers page states teammates span the globe and references benefits/values including tokens, PTO, office/remote flexibility and parental leave. | partially verified medium | SRC-021 |
| EC-019 | Injective Terms of Use dated April 16, 2026 include an important prohibited-person notice and restricted jurisdictions/persons. | verified high | SRC-022 |
| EC-020 | CourtListener exact public searches returned zero results for Injective Protocol and for INJ token Injective in-session. | partially verified medium | SRC-023 |
| EC-021 | Helix describes itself as a premier decentralized spot and derivatives exchange, and Mito describes automated trading vaults and launchpad products. | partially verified medium | SRC-025SRC-026SRC-002 |
| EC-022 | Competitor public sources show Injective competes with dYdX, Hyperliquid, Sei and Solana/Ethereum-like ecosystems for finance/trading workloads. | verified medium | SRC-028SRC-029SRC-030SRC-031 |
| EC-023 | Public sources did not provide audited financials, projections, customer revenue, cap table, token ledger, contracts, insurance, compensation, incentive plans or complete legal schedules. | not publicly verifiable high | SRC-001SRC-004SRC-013SRC-019SRC-022 |
| EC-024 | Public legal/IP review found several permissively licensed SDK repositories but no comprehensive patent/trademark clearance, insurance, material contract or regulatory correspondence evidence. | partially verified medium | SRC-009SRC-010SRC-011SRC-012SRC-022SRC-023 |
| EC-025 | Injective Labs describes itself as an R&D company and one of the core contributors to Injective, contributing to Injective, Helix, validator nodes and Mito. | verified high | SRC-002 |
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.